Christopher Lucas on DNA Nanobots, Non-Viral Gene Therapy & Biotech Investing with Purpose | Modern Investing Podcast
Fri Oct 03 2025
Message the Host
In this episode, we dive into the fast-moving frontier of biotech innovation and precision medicine with Christopher Lucas, co-founder of DNA Nanobots, a platform creating non-viral gene therapies designed to save lives, reduce toxicity, and democratize access to cutting-edge treatments.
Chris brings a rare blend of deep scientific expertise and business savvy to the conversation, sharing how his team is reimagining drug delivery using DNA itself as a building block to target diseases with precision, efficiency, and safety.
We explore:
How DNA Nanobots builds non-viral delivery systems from the gene itselfWhy this technology could replace viral vectors for gene therapy, lowering cost and enabling re-dosingThe company’s breakthrough partnerships in Duchenne Muscular Dystrophy (DMD), lysosomal storage diseases, and acute myeloid leukemiaHow they’re balancing platform strategy and single-asset development to hedge against biotech market cyclesWhy Chris and his co-founder believe success = saving even one lifeFundraising lessons from biotech, navigating early-stage VC, proof-of-concept milestones, and partner collaborationsKey advice for new biotech investors on identifying early signals, managing risk, and finding trustworthy teamsWhether you're a startup founder, an early-stage investor, or simply biotech-curious, this episode gives you a front-row seat to the future of personalized medicine.
🎧 Listen now and discover how the next wave of biotech could transform medicine, and how smart investors can be part of it.
👤 About Christopher Lucas:
Chris is the co-founder and officer of DNA Nanobots, a biotech platform pioneering non-viral gene delivery systems that promise safer, more targeted, and cost-effective therapies. With a PhD in biomedical sciences and a postdoc in mechanical engineering from The Ohio State University, Chris has spent the last decade pushing the boundaries of drug delivery to make precision therapies more accessible.
Click Here to Check Out Our Upcoming Online
Investing Events
About Sidepocket:
If you don't have the time to professionally trade and are tired of being at the whim of the market's ups and downs, consider using Sidepocket to automate investing.
Sidepocket monitors the markets 24/7 and automatically rebalances your holdings each month. To maximize returns while protecting against loss.
That's why Sidepocket applies sophisticated quantitative methods, including tactical asset allocation to systematically minimize these drawdowns and consistently protect and grow your hard earned savings.
To learn more, visit www.sidepocket.com
More
Message the Host In this episode, we dive into the fast-moving frontier of biotech innovation and precision medicine with Christopher Lucas, co-founder of DNA Nanobots, a platform creating non-viral gene therapies designed to save lives, reduce toxicity, and democratize access to cutting-edge treatments. Chris brings a rare blend of deep scientific expertise and business savvy to the conversation, sharing how his team is reimagining drug delivery using DNA itself as a building block to target diseases with precision, efficiency, and safety. We explore: How DNA Nanobots builds non-viral delivery systems from the gene itselfWhy this technology could replace viral vectors for gene therapy, lowering cost and enabling re-dosingThe company’s breakthrough partnerships in Duchenne Muscular Dystrophy (DMD), lysosomal storage diseases, and acute myeloid leukemiaHow they’re balancing platform strategy and single-asset development to hedge against biotech market cyclesWhy Chris and his co-founder believe success = saving even one lifeFundraising lessons from biotech, navigating early-stage VC, proof-of-concept milestones, and partner collaborationsKey advice for new biotech investors on identifying early signals, managing risk, and finding trustworthy teamsWhether you're a startup founder, an early-stage investor, or simply biotech-curious, this episode gives you a front-row seat to the future of personalized medicine. 🎧 Listen now and discover how the next wave of biotech could transform medicine, and how smart investors can be part of it. 👤 About Christopher Lucas: Chris is the co-founder and officer of DNA Nanobots, a biotech platform pioneering non-viral gene delivery systems that promise safer, more targeted, and cost-effective therapies. With a PhD in biomedical sciences and a postdoc in mechanical engineering from The Ohio State University, Chris has spent the last decade pushing the boundaries of drug delivery to make precision therapies more accessible. Click Here to Check Out Our Upcoming Online Investing Events About Sidepocket: If you don't have the time to professionally trade and are tired of being at the whim of the market's ups and downs, consider using Sidepocket to automate investing. Sidepocket monitors the markets 24/7 and automatically rebalances your holdings each month. To maximize returns while protecting against loss. That's why Sidepocket applies sophisticated quantitative methods, including tactical asset allocation to systematically minimize these drawdowns and consistently protect and grow your hard earned savings. To learn more, visit www.sidepocket.com